

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/023703 A1

(51) International Patent Classification:

A61K 31/4155 (2006.01) *A61K 31/519* (2006.01)
A61K 31/4196 (2006.01) *A61K 31/565* (2006.01)
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/IB2023/057537

(22) International Filing Date:

25 July 2023 (25.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/393,504	29 July 2022 (29.07.2022)	US
63/468,677	24 May 2023 (24.05.2023)	US
63/470,365	01 June 2023 (01.06.2023)	US

(71) Applicants: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **CTXT PTY LTD** [AU/AU]; 305 Grattan Street, Parkville, Melbourne, 3000 (AU).

(72) Inventors: **GREENWALD, Eric Chris**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **HOMJI MISHRA, Natasha Farrokh**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California

(US). **KOWALSKI, Karen Leann**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **LI, Meng**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **LIU, Li**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **ZHENG, Jingwen**; 2822 Jason Court, Thousand Oaks, California 91362 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: DOSING REGIMENS COMPRISING A KAT6 INHIBITOR FOR THE TREATMENT OF CANCER

(57) Abstract: The invention relates to dosing regimens for the treatment of cancer comprising administering to a subject in need thereof a daily dose of a lysine acetyltransferase 6 (KAT6) inhibitor as a single agent or in combination with: a) a cyclin-dependent kinase 4 (CDK4) inhibitor; b) an antiestrogen; or c) a CDK4 inhibitor and an antiestrogen.

FIGURE 2A





FIGURE 2B



WO 2024/023703 A1

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*